Search Results for: ABUSE DETERRENT TECHNOLOGY New Abuse
Articles
ABUSE DETERRENT TECHNOLOGY - New Abuse Deterrent Formulation Technology for Immediate-Release Opioids October 16, 2013
Johannes Bartholomäus͛, PhD; Sebastian Schwier, PhD; Martin Brett, et al, review how the INTAC technology platform has been extended to IR formulations with the intention to deter non-oral routes of abuse.
PEGYLATION - PEGylation - Three Decades of Product Approvals & Technology Development October 1, 2020
Esay Okutgen, PhD, Alper Orhan, MSc, and Josef Bossart, PhD, believe with the 30-year anniversary of the first product approval using PEG (polyethylene oxide polymer) conjugation, it seems an appropriate occasion to review the evolution of the technology (PEGylation) and subsequent product approvals.
KemPharm & Genco Sciences Announce Technology Licensing Agreement October 5, 2017
KemPharm, Inc., a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, recently announced it has...Egalet Receives FDA Approval for Extended-Release Product Formulated With Abuse-Deterrent Properties January 17, 2017
Egalet Corporation recently announced the US FDA has approved ARYMO ER (morphine sulfate) extended-release (ER) tablets C-II for the management...Patheon Selected by Grünenthal to Develop Drugs Using INTAC(R) Abuse-Deterrent Formulations Technology April 25, 2016
Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with...Patheon Selected By Grünenthal to Develop Drugs Using INTAC(R) Abuse-Deterrent Formulations Technology April 19, 2016
Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement...Collegium Announces FDA Acceptance of IND Application for Abuse-Deterrent Analgesic January 26, 2016
Collegium Pharmaceutical, Inc. recently announced the US FDA has accepted the company’s investigational new drug (IND) application to begin a...LIPID-BASED DELIVERY SYSTEMS - New Approaches for Macromolecule Oral Delivery, Abuse Deterrence & Bioavailability Enhancement March 31, 2015
Julien Meissonnier reviews the development of a broad range of advanced oral drug delivery technologies, including a toolkit of technologies based upon the broad application of lipid-based drug delivery systems for optimum solubility enhancement.
ABUSE-DETERRENT MARKET - What’s in the Pipeline? Abuse-Deterrent Products November 18, 2014
Tugrul Kararli, PhD, MBA, Kurt Sedo, and Josef Bossart, PhD, decided it would be interesting to interrogate the PharmaCircle database and see what successes have been achieved with respect to abuse-deterrent formulations in terms of approved and pipeline products.
ROUNDTABLE DISCUSSION: Reformulating Opioids to Deter Abuse January 8, 2014
Contributor Cindy H. Dubin talks with some leading Specialty Pharma companies to find out how they are formulating technologies to deter the growing problem of opioid abuse.
Atlantic Pharmaceuticals Announces Successful Pre-IND Meeting for Abuse-Deterrent Hydrocodone August 20, 2013
Atlantic Pharmaceuticals, Inc.recently announced it has completed a successful Pre-Investigational New Drug Meeting with the FDA on a single-component, immediate...FDA Makes Decision on Abuse-Deterrent Formulations of Oxycontin Drug Products April 22, 2013
Grünenthal recently announced it is pleased with the US Food and Drug Administration's (FDA) recent decisions regarding abuse-deterrent formulations (ADF)...INTAC Technology Combats Misuse of Extended-Release Drugs May 14, 2012
During this year's Annual Scientific Meeting of the American Pain Society (May 16-19, 2012, Honolulu, HI), Grunenthal presented results from...Protega Pharmaceuticals LLC Announces Commercialization of Oxycodone Hydrochloride Tablets CII in the US July 6, 2022
Protega Pharmaceuticals LLC recently announced the commercial launch of RoxyBond (oxycodone) immediate-release (IR) tablets in the US. RoxyBond was approved...Ensysce Biosciences Receives Notice of Award for Year 3 of Multi-Year NIDA Grant for the Clinical Development of its Next-Generation Opioid Products With Overdose Protection July 8, 2021
Ensysce Biosciences, Inc. recently announced receipt of the third year award of a multi-year grant from the National Institute on...2019 Analytical Testing in Drug Development eBook - Regulations Help Propel Testing Market September 6, 2019
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
GLOBAL REPORT - 2018 Global Drug Delivery & Formulation Report: Part 1, a Global Review March 1, 2019
In part 1 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on a global review of 2018 product approvals.
Elite Pharmaceuticals Announces Strategic Marketing Alliance With Glenmark Pharmaceuticals June 6, 2018
Elite Pharmaceuticals, Inc recently announced the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals, Inc., USA to...GLOBAL REPORT - 2017 Global Drug Delivery & Formulation Report: Part 2, Notable Product Approvals of 2017 April 5, 2018
In part 2 of this 4-part series, PharmaCircle in collaboration with Drug Development & Delivery, reviews the more interesting individual products approved throughout the past year.
GLOBAL REPORT - 2017 Global Drug Delivery & Formulation Report: Part 1, a Global Review March 15, 2018
In part 1 of this 4-part series, PharmaCircle in collaboration with Drug Development & Delivery, focuses on the macro aspects of the 2017 product approvals.
Issues
October 2012
COVER DRUG DEVICES – The Rise of the Bolus Injector – A New Device Class Enabling Long-Duration Subcutaneous Administration of...
